<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625014</url>
  </required_header>
  <id_info>
    <org_study_id>P05.009</org_study_id>
    <nct_id>NCT00625014</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans</brief_title>
  <official_title>Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesized that short-term treatment with haloperidol induces insulin resistance through
      a mechanistic route that is independent of weight gain. We therefore treated healthy
      non-obese men with haloperidol for 8 days, and studied the impact of these intervention on
      glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution
      technology and indirect calorimetry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of subchronic haloperidol treatment on HGO, whole body peripheral glucose disposal, fatty acid flux and fuel oxidation.</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy men</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol 3 mg/day for 8 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men

          -  20 kg/m2 &lt; BMI &lt; 26 kg/m2

          -  Age 20-40 years

          -  FPG &lt; 6 mmol/L

        Exclusion Criteria:

          -  FPG &gt; 6 mmol/L

          -  BMI &gt; 26 kg/m2

          -  Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present
             or in the past.

          -  A positive family history of schizophrenia

          -  Any significant chronic disease

          -  Renal, hepatic or endocrine disease

          -  Use of medication known to influence lipolysis and/or glucose metabolism

          -  Total cholesterol &gt; 7mmol/L and/or triglycerides &gt; 2 mmol/L

          -  Recent weight changes or attempts to loose weight (&gt; 3 kg weight gain or loss, within
             the last 3 months)

          -  Difficulties to insert an intravenous catheter

          -  Smoking (current)

          -  Severe claustrophobia (ventilated hood)

          -  Recent blood donation (within the last 2 months)

          -  Recent participation in other research projects (within the last 3 months),
             participation in 2 or more projects in one year

          -  Extensive sporting activities (more than 10 hours of exercise per week)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>February 19, 2008</last_update_submitted>
  <last_update_submitted_qc>February 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof H Pijl</name_title>
    <organization>Leiden University Medical Center</organization>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Haloperidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

